- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00526045
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients
A Phase I Dose Escalation, Multi-center, Open-label Study of AUY922 Administered IV on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies Including Phase II Expansion Arms in Patients With Either HER2 Positive or ER Positive Locally Advanced or Metastatic Breast Cancer.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Sutton, Det Forenede Kongerige, SM2 5PT
- Novartis Investigative Site
-
-
-
-
California
-
Los Angeles, California, Forenede Stater, 90095
- UCLA/ University of California Los Angeles UCLA
-
-
Georgia
-
Augusta, Georgia, Forenede Stater, 30912
- Georgia Health Sciences University Med College of GA
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101
-
-
Missouri
-
Saint Louis, Missouri, Forenede Stater, 63110
- Washington University School Of Medicine-Siteman Cancer Ctr Dept. of Siteman Cancer Ctr.
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89135
- Nevada Cancer Institute Clinical Trials Office
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030-4009
- MD Anderson Cancer Center/University of Texas Thoractic Head/Neck Med.Onc(2)
-
San Antonio, Texas, Forenede Stater, 78229
- Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3)
-
-
-
-
-
Groningen, Holland, 9713 GZ
- Novartis Investigative Site
-
-
-
-
-
Bellinzona, Schweiz, 6500
- Novartis Investigative Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Dose-escalation and MTD dose expansion arm: Patients with histologically confirmed, advanced malignant solid tumors whose disease has progressed on standard therapy or for whom no standard therapy exists.
Breast cancer phase II expansion arms only:
Females patients with HER2 positive non-operable locally advanced or metastatic breast cancer must have:
- History of trastuzumab resistance, defined as either local or systemic disease progression on treatment with at least 8 weeks of a trastuzumab containing regimen.
- Received up to 3 prior anti HER2 based regimens (i.e. trastuzumab and/or lapatinib in combination with other agents) for metastatic disease
- Patients who develop metastases while receiving adjuvant or neo-adjuvant trastuzumab are eligible.
HER2 positive patients, tumor/s must demonstrate HER2 over-expression based on either:
- Immunohistochemistry (IHC) at the 3+ level, or
- IHC 2+ confirmed by fluorescence in-situ hybridization (FISH). Tumors tested by FISH must be positive by the specific FISH assay for the amplification of HER2.
- Female patients with ER positive non-operable locally advanced or metastatic breast cancer patients who received standard sequence lines of endocrine therapy and whose disease has progressed on at least one and up to 3 lines of endocrine and/or cytotoxic therapy for advanced disease.
- All patients must have at least one measurable lesion as defined by RECIST. Irradiated lesions are only evaluable for disease progression.
- All patients must have progressive disease before entering the study
- Age ≥ 18 years.
- World Health Organization (WHO) Performance Status of ≤ 2.
- Life expectancy of ≥ 12 weeks.
- Absolute Neutrophil Count (ANC) 1.5 x 109/L; hemoglobin (Hgb) 9 g/dl; platelets (plt) 100 x 109/L; potassium, calcium, magnesium and phosphorus within normal limits or correctable with supplements; AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present; serum bilirubin 1.5 x ULN; serum albumin > 2.5g/dl and serum creatinine 1.5 x ULN or 24-hour clearance 50 ml/min
Exclusion criteria:
Patients with CNS metastasis which are:
- Symptomatic or
- Require treatment for symptom control and/or
- Growing
Note: patients without clinical signs or symptoms of CNS involvement are not required to have a CT/MRI of the brain
- Prior treatment with any HSP90 or HDAC inhibitor compound.
Patient who received systemic anti-cancer treatment prior to the first dose of AUY922 within the following time frames:
- Chemotherapy within 4 weeks
- Radiotherapy within 4 weeks
- Palliative radiotherapy: within 2 weeks
- Trastuzumab treatment within 4 weeks
- Nitrosoureas, mitomycin and monoclonal antibodies (except trastuzumab): within 6 weeks
- Any continuous-dosing (i.e. daily dosing, every-other-day dosing, Monday- Wednesday-Friday dosing, weekly etc) of systemic anticancer treatment for which the recovery period is not known, or investigational drugs (i.e. targeted agents) within a duration of ≤ 5 half lives of the agent and their active metabolites (if any)
- Patients who have not recovered from side effects of previous systemic anticancer therapy to less than grade 2 CTCAE prior to the first dose.
- Pregnant or lactating women.
Cardia exclusion criteria:
- History (or family history) of long QT syndrome.
- Mean QTc ≥ 450 msec on screening ECG
- History of clinically manifest ischemic heart disease including myocardial infarction, stable or unstable angina, coronary arteriography or cardiac stress testing/imaging with findings consistent with coronary occlusion or infarction, ≤ 6 months prior to study start.
- History of heart failure or left ventricular (LV) dysfunction (LVEF ≤ 45%) by MUGA or ECHO
- Known diagnosis of HIV infection (HIV testing is not mandatory).
- Acute or chronic liver disease, acute or chronic renal disease or other concurrent severe and/or uncontrolled medical conditions (e.g. uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol.
- Cardiac exclusion criteria:
Mean QTc ≥ 450 msec on screening ECG and clinically significant ECG abnormalities including one or more of the following: left bundle branch block (LBBB), right bundle branch block (RBBB) with left anterior hemiblock (LAHB). ST segment elevations or depressions > 1mm, or 2nd (Mobitz II) or 3rd degree AV block; clinically significant ECG abnormalities including one or more of the following: left bundle branch block (LBBB), right bundle branch block (RBBB) with left anterior hemiblock (LAHB). ST segment elevations or depressions > 1mm, or 2nd (Mobitz II) or 3rd degree AV block.
History (or family history) of long QT syndrome, heart failure or left ventricular (LV) dysfunction (LVEF ≤ 45%) by MUGA or ECHO, history of clinically manifest ischemic heart disease including myocardial infarction, stable or unstable angina, coronary arteriography or cardiac stress testing/imaging with findings consistent with coronary occlusion or infarction, ≤ 6 months prior to study start; history or presence of atrial fibrillation, atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de Pointes.
Other protocol-defined inclusion/exclusion criteria may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Eskalering
|
|
Eksperimentel: HER2 Positive
|
|
Eksperimentel: ER+ breast cancer
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
The safe dose of AUY922 when administered once a week
Tidsramme: 54 weeks (MTD determination)
|
54 weeks (MTD determination)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Efficacy of AUY922 administered once a week
Tidsramme: Baseline, and every 2 cycles (time to document tumor progression)
|
Baseline, and every 2 cycles (time to document tumor progression)
|
Pharmacokinetics of AUY922 and Pharmacodynamics by PET response, blood and tumor biomarkers at baseline and post-AUY922
Tidsramme: Baseline and every 2 cycles
|
Baseline and every 2 cycles
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CAUY922A2101
- 2006-002766-20 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Ontario Clinical Oncology Group (OCOG)Afsluttet
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...UkendtBRCA1 mutation | Breast Cancer Invasive NosPolen
-
Aga Khan UniversityAfsluttetBrystkræft | Perforatorklap | Brysttumor | Oncoplasty | Breast-QPakistan
-
University Health Network, TorontoAfsluttetBreast Cancer Invasive Nos | Primær invasiv brystkræftCanada
-
KU LeuvenNovartisUkendtER Positive, HER2 Negative Breast Cancer NeoplasmaBelgien
Kliniske forsøg med AUY922 2 mg/m2
-
University of California, San FranciscoTau Consortium; CBD SolutionsAfsluttetProgressive Supranuclear Parese (PSP) | Corticobasal degeneration (CBD) | Corticobasalt syndrom (CBS) | Primære fire gentagne tauopatier (4RT)Forenede Stater
-
University of California, San FranciscoAfsluttetAlzheimers sygdomForenede Stater
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Ukendt
-
Lee's Pharmaceutical LimitedUkendtOvarieepitelkræft | Æggelederkræft | Primær peritoneal kræftKina
-
Chengdu Zenitar Biomedical Technology Co., LtdRekrutteringDiffust storcellet B-celle lymfom, DLBCLKina
-
Italian Sarcoma GroupFrench Sarcoma Group; Grupo Espanol de Investigacion en SarcomasAktiv, ikke rekrutterendeLokaliserede højrisiko bløddelssarkomer i ekstremiteter og kropsvæg hos voksneSpanien, Italien
-
Krzysztof MisiukiewiczSanofi; Icahn School of Medicine at Mount SinaiAfsluttet
-
NanOlogy, LLCUS Biotest, Inc.AfsluttetOvariekarcinomForenede Stater
-
Johns Hopkins All Children's HospitalAfsluttetTumorer i centralnervesystemetForenede Stater
-
Prof. Dr. med. Claus RödelAktiv, ikke rekrutterende